KalVista Pharma CCO Sweeny Sold $61,878 in Stock
#KalVista Pharmaceuticals #Nicole Sweeny #Insider Trading #EKTERLY #Stock Sale #Analyst Ratings #Hereditary Angioedema Treatment #Market Outperform
📌 Key Takeaways
- KalVista Pharma CCO sold $61,878 in company stock to cover tax obligations
- The stock has delivered 46% return over the past year and appears undervalued
- KalVista reported Q4 revenue of $35 million, exceeding analyst expectations
- Multiple analysts have raised price targets following strong EKTERLY sales performance
📖 Full Retelling
KalVista Pharmaceuticals Chief Commercial Officer Nicole Sweeny sold $61,878 worth of company stock on February 23, 2026, disposing of 3,975 shares at an average price of $15.5668 to cover tax obligations related to the vesting of Restricted Stock Units. The transaction, detailed in a Form 4 filing with the Securities and Exchange Commission, saw individual sales prices ranging from $15.5101 to $15.566982 per share. Interestingly, this sale followed Sweeny's acquisition of 11,250 shares on February 21 and 22 through the exercise of Restricted Stock Units. KalVista's stock has demonstrated strong performance, delivering a 46% return over the past year and currently trading at $15.77 with a market capitalization of $800 million. According to InvestingPro analysis, the stock appears undervalued at current levels, with a Fair Value estimated at $18.07. The stock sale comes amid positive developments for KalVista, as the company reported preliminary fourth-quarter 2025 revenue of approximately $35 million for its oral hereditary angioedema treatment EKTERLY, significantly exceeding analyst expectations of $20 million. This strong performance contributed to a full-year revenue of approximately $49 million for the treatment, which launched in July 2025. The positive results have led to several bullish analyst actions, with Stifel reiterating a Buy rating and setting a price target of $39.00, Needham increasing its target from $32.00 to $35.00 while maintaining a Buy rating, and Citizens raising its target from $28.00 to $29.00 with a Market Outperform rating. Additionally, EKTERLY has been recommended as a first-line therapy for acute hereditary angioedema attacks in adolescents by a newly published International Guideline.
🏷️ Themes
Executive Stock Transactions, Pharmaceutical Performance, Market Analysis
📚 Related People & Topics
Insider trading
Trading using nonpublic information
# Insider Trading **Insider trading** is the trading of a public company's stock or other securities (such as bonds or stock options) based on **material, nonpublic information** about the company. While the practice is common, its legality is subject to complex regulations that vary significantly ...
Entity Intersection Graph
Connections for Insider trading:
🌐
SEC filing
5 shared
👤
New York Stock Exchange
4 shared
👤
Rachel Haurwitz
3 shared
🌐
ZWS
2 shared
🌐
Biopharmaceutical
2 shared
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Bitcoin slips, wipes out 50% from October record high at session low AMD stock surges 14% on Meta AI partnership deal Wall Street ends higher on tech rebound ahead of State of the Union address Software stocks rebound as Anthropic partnerships ease AI disruption fears (South Africa Philippines Nigeria) KalVista Pharma CCO Sweeny Sold $61,878 in Stock By Investing.com Insider Trading Published 02/24/2026, 07:55 PM KalVista Pharma CCO Sweeny Sold $61,878 in Stock 0 KALV 1.35% Nicole Sweeny, Chief Commercial Officer of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) , sold 3,975 shares of common stock on February 23, 2026, for approximately $61,878. The shares were sold at a weighted average price of $15.5668, with individual sales prices ranging from $15.5101 to $15.566982. The stock has delivered a strong 46% return over the past year, currently trading at $15.77 with a market cap of $800 million. According to InvestingPro analysis, KALV appears undervalued at current levels, with a Fair Value of $18.07. According to a Form 4 filing with the Securities and Exchange Commission, the sale was to cover tax withholding obligations related to the vesting and settlement of Restricted Stock Units and was not a discretionary transaction. On February 21 and 22, Sweeny also acquired a total of 11,250 shares of KalVista Pharmaceuticals’ common stock through the exercise of Restricted Stock Units. InvestingPro offers 11 additional tips for KALV investors seeking deeper insights into the company’s financial health and prospects. In other recent news, KalVista Pharmaceuticals, Inc. reported preliminary fourth-quarter 2025 revenue results for its oral hereditary angioedema treatment, EKTERLY, totaling approximately $35 million. This revenue significantly exceeded analyst expectations, which were around $20 million, and contributed to a full-year revenue of approximately $49 million. The strong performance of EKTERLY, which launc...
Read full article at source